U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Why Is Laser Photonics Stock Falling On Thursday?

Laser Photonics Corp (NASDAQ:LASE) stock dips on Thursday. Read why traders are taking profits ahead of Q1 earnings despite major Department of War and Johnson & Johnson deals.

10 Health Care Stocks Whale Activity In Today's Session

Johnson & Johnson Announces New Biomarker Exploratory Analyses From The Phase 2 DAHLIAS Study Evaluating Nipocalimab In Adults With Moderate-To-Severe Sjögren's Disease

· Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune function·· Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren'

Johnson & Johnson Reports Lupus Study Results for Nipocalimab

Johnson & Johnson (NYSE:JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to demonstrate sustained

Johnson & Johnson Reports New Sjögren's Disease Data for Nipocalimab

Johnson & Johnson (NYSE:JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjögren's disease

Johnson & Johnson Announces Updated Results From Phase 1/1b CHRYSALIS-2 Study Evaluating Intravenous RYBREVANT In Combination With LAZCLUZE In Patients With Advanced NSCLC With Atypical E

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated diseaseConsistent responses observed across atypical EGFR

Johnson & Johnson Announces New Data From Its Phase 3 MajesTEC-9 Study That Show Clinically Meaningful And Statistically Significant Survival Improvements With TECVAYLI In Patients With R

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant

Johnson & Johnson Wins FDA Nod for New TREMFYA Benefit in Psoriatic Arthritis Treatment

Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the TREMFYA® (guselkumab)

Laser Photonics Subsidiary, CMS Laser, Receives $250K Order From Johnson & Johnson For Custom On-The-Fly Laser Drilling System With Integrated Vision

$250K Development System Order from Johnson & Johnson Represents Entry into Medical Device Manufacturing; Successful Validation Could Enable Broader Deployment Across Manufacturing LinesORLANDO, FL / ACCESS Newswire